https://scholars.lib.ntu.edu.tw/handle/123456789/617102
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.author | CHIUN HSU | en_US |
dc.contributor.author | Rimassa L. | en_US |
dc.contributor.author | Sun H.-C. | en_US |
dc.contributor.author | Vogel A. | en_US |
dc.contributor.author | Kaseb A.O. | en_US |
dc.date.accessioned | 2022-08-19T00:20:31Z | - |
dc.date.available | 2022-08-19T00:20:31Z | - |
dc.date.issued | 2021 | - |
dc.identifier.issn | 1758-8340 | - |
dc.identifier.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85111475007&doi=10.1177%2f17588359211031141&partnerID=40&md5=715daa24c061bb51ee109c493b32fd33 | - |
dc.identifier.uri | https://scholars.lib.ntu.edu.tw/handle/123456789/617102 | - |
dc.publisher | SAGE Publications Inc. | - |
dc.relation.ispartof | Therapeutic Advances in Medical Oncology | - |
dc.title | Immunotherapy in hepatocellular carcinoma: evaluation and management of adverse events associated with atezolizumab plus bevacizumab | en_US |
dc.type | review | en |
dc.identifier.doi | 10.1177/17588359211031141 | - |
dc.identifier.scopus | 2-s2.0-85111475007 | - |
dc.relation.journalvolume | 13 | - |
item.openairetype | review | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.cerifentitytype | Publications | - |
item.fulltext | no fulltext | - |
item.grantfulltext | none | - |
crisitem.author.dept | Oncology | - |
crisitem.author.dept | Medical Oncology-NTUCC | - |
crisitem.author.orcid | 0000-0002-1122-0055 | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Cancer Center (NTUCC) | - |
顯示於: | 腫瘤醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。